| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.21M | 13.76M | 27.25M | 32.35M | 23.98M | 27.86M |
| Gross Profit | 2.31M | 2.17M | 2.85M | 2.54M | 164.00K | -571.00K |
| EBITDA | -30.06M | -30.49M | -23.74M | -42.55M | -44.21M | -12.04M |
| Net Income | -38.95M | -48.13M | -39.57M | -55.74M | -57.01M | -29.60M |
Balance Sheet | ||||||
| Total Assets | 81.13M | 79.80M | 108.95M | 133.56M | 173.13M | 234.99M |
| Cash, Cash Equivalents and Short-Term Investments | 96.00K | 255.00K | 135.00K | 187.00K | 1.19M | 102.00K |
| Total Debt | 200.11M | 193.26M | 121.04M | 171.57M | 166.50M | 160.50M |
| Total Liabilities | 247.80M | 247.29M | 228.85M | 213.88M | 197.41M | 200.97M |
| Stockholders Equity | -166.51M | -167.40M | -119.90M | -80.32M | -24.27M | 34.01M |
Cash Flow | ||||||
| Free Cash Flow | 47.00K | -78.00K | -53.00K | -1.01M | 1.10M | -1.22M |
| Operating Cash Flow | 48.00K | -75.00K | -27.00K | -1.00M | 1.41M | -1.22M |
| Investing Cash Flow | -1.00K | -3.00K | -26.00K | -2.00K | -303.00K | 1.28M |
| Financing Cash Flow | -202.00K | 193.00K | 0.00 | 0.00 | -12.00K | -51.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | HK$108.80M | 3.35 | 16.22% | ― | -18.25% | -8.37% | |
68 Neutral | HK$221.28M | 5.01 | 4.73% | ― | -20.52% | -68.47% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
46 Neutral | HK$23.95M | -1.26 | -12.82% | ― | 31.75% | 21.89% | |
45 Neutral | HK$174.00M | -0.25 | -296.26% | ― | -49.77% | -1095.34% | |
43 Neutral | HK$93.00M | -0.30 | ― | ― | -11.12% | -1.86% | |
40 Underperform | HK$179.55M | -0.46 | -30.61% | ― | -20.20% | -33.73% |
Grace Life-tech Holdings Limited, currently under joint provisional liquidation and restructuring, reported ongoing efforts to expand its plant stem cell business by adding new customers in the fourth quarter of 2025 and deepening supplier collaboration, while tightly controlling administrative expenses and avoiding significant capital expenditure. The company is formulating a comprehensive debt restructuring plan covering its outstanding bank loans and notes, is in advanced discussions with at least one potential investor that has completed legal due diligence, is seeking further financing and restructuring options with other institutions, and is negotiating potential strategic collaborations with a partner in investment and real estate, steps that are aimed at resolving going-concern issues and stabilising its financial position for stakeholders.
The most recent analyst rating on (HK:2112) stock is a Hold with a HK$0.06 price target. To see the full list of analyst forecasts on Grace Life-tech Holdings Limited stock, see the HK:2112 Stock Forecast page.
Grace Life-tech Holdings Limited has implemented several measures to address its going concern issue, including expanding its plant stem cell business and engaging new customers. The company is working on a debt restructuring proposal and has entered into an interest waiver agreement, waiving approximately US$9.9 million of accrued interest. Additionally, Grace Life-tech has partnered with a strategic partner in the PRC to expand its operations and is controlling administrative costs to optimize efficiency.